CRISPR BASED GENOME EDITING OF HUMAN T CELLS TO TARGET H3.3K27M MUTATION IN GLIOMAS

被引：0
|
作者：
Hegde, Bindu [1 ]
Roth, Theodore [1 ]
Nguyen, David [1 ]
Chheda, Zinal [1 ]
Apathy, Ryan [1 ]
Marson, Alex [1 ]
Okada, Hideho [2 ]
机构：
[1] UCSF, San Francisco, CA USA
[2] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IMMU-38
引用
收藏
页码：127 / 127
页数：1
相关论文
共 50 条
  • [1] Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation
    Funato, Kosuke
    Major, Tamara
    Lewis, Peter W.
    Allis, C. David
    Tabar, Viviane
    SCIENCE, 2014, 346 (6216) : 1529 - 1533
  • [2] IMPACT OF H3.3K27M MUTATION ON CANCER EPIGENOME
    Fang, Dong
    Zhang, Zhiguo
    NEURO-ONCOLOGY, 2015, 17 : 8 - 9
  • [3] Identification of a novel and a shared H3.3K27M mutation derived neoantigen epitope and H3.3K27M specific TCR engineered T cell therapy for glioma
    Chheda, Zinal
    Kohanbash, Gary
    Sidney, John
    Okada, Kaori
    Jahan, Naznin
    Carrera, Diego
    Watchmaker, Payal
    Downey, Kira
    Liu, Shuming
    Shrivastav, Shruti
    Mueller, Sabine
    Pollack, Ian F.
    Carcaboso, Angel M.
    Sette, Alessandro
    Hou, Yafei
    Okada, Hideho
    CANCER RESEARCH, 2017, 77
  • [4] Targeting the reprogrammed metabolism in H3.3K27M pediatric high-grade gliomas
    Magalhaes, Eduardo S. de Camargo
    de Bont, Eveline S. J. M.
    Bruggeman, Sophia W. M.
    Lima, Flavia R. S.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2024, 1870 (06):
  • [5] Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas
    Mota, Mateus
    Sweha, Stefan R.
    Pun, Matt
    Natarajan, Siva Kumar
    Ding, Yujie
    Chung, Chan
    Hawes, Debra
    Yang, Fusheng
    Judkins, Alexander R.
    Samajdar, Susanta
    Cao, Xuhong
    Xiao, Lanbo
    Parolia, Abhijit
    Chinnaiyan, Arul M.
    Venneti, Sriram
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (18)
  • [6] TARGETING EPIGENETIC VULNERABILITIES IDENTIFIED FROM A CRISPR SCREEN IN H3.3K27M DIPG
    Panditharatna, Eshini
    Dharia, Neekesh
    Li, Deyao
    Beck, Alexander
    Shaw, McKenzie
    Jiang, Li
    Trissal, Maria
    Liu, Ilon
    Lareau, Caleb
    Anastas, Jamie
    Quezada, Michael
    Hack, Olivia
    Mire, Hafsa
    Jerome, William
    Kugener, Guillaume
    Root, David
    Vazquez, Francisca
    Dai, Lingling
    Wang, Tingjian
    Mathewson, Nathan
    Shi, Yang
    Stegmaier, Kimberly
    Monje, Michelle
    Golub, Todd
    Qi, Jun
    Filbin, Mariella
    NEURO-ONCOLOGY, 2020, 22 : 95 - 95
  • [7] Use of cerebral organoids to model pediatric gliomas with H3.3K27M and H3.3G34R
    Ismail, Amin
    CANCER RESEARCH, 2015, 75
  • [8] H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma
    Immisch, Lena
    Papafotiou, George
    Popp, Oliver
    Mertins, Philipp
    Blankenstein, Thomas
    Willimsky, Gerald
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
  • [9] The H3.3K27M oncohistone antagonizes reprogramming in Drosophila
    Ahmad, Kami
    Henikoff, Steven
    PLOS GENETICS, 2021, 17 (07):
  • [10] PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M MIDLINE GLIOMAS
    Mueller, Sabine
    Lulla, Rishi
    Goldman, Stewart
    Banerjee, Anu
    Chi, Susan
    Whipple, Nicholas
    Crawford, John
    Gauvain, Karen
    Nazemi, Kellie
    Nazarian, Javad
    Taitt, Jared
    Watchmaker, Payal
    Nejo, Takahide
    Okada, Kaori
    Butterfield, Lisa
    Molinaro, Annette
    Prados, Michael
    Okada, Hideho
    NEURO-ONCOLOGY, 2019, 21 : 284 - 285
12345